Evoke Pharma, Inc.
EVOK
$3.17
-$0.13-3.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 24.65% | 4.03% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 24.65% | 4.03% | |||
| Cost of Revenue | 13.94% | 150.60% | |||
| Gross Profit | 25.08% | 1.61% | |||
| SG&A Expenses | 14.63% | 2.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.27% | 4.37% | |||
| Operating Income | 7.16% | -5.08% | |||
| Income Before Tax | 9.11% | -3.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.11% | -3.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.11% | -3.57% | |||
| EBIT | 7.16% | -5.08% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 63.39% | -3.57% | |||
| Normalized Basic EPS | 63.39% | -3.55% | |||
| EPS Diluted | 63.39% | -3.57% | |||
| Normalized Diluted EPS | 63.39% | -3.55% | |||
| Average Basic Shares Outstanding | 148.25% | 0.00% | |||
| Average Diluted Shares Outstanding | 148.25% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||